NeuroPace, Inc.
NeuroPace, Inc. (NPCE) Stock Competitors & Peer Comparison
See (NPCE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NPCE | $16.80 | -0.41% | 565.6M | -25.45 | -$0.66 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $91.13 | -1.46% | 158.4B | 25.53 | $3.57 | +2.67% |
| SYK | $327.51 | -0.65% | 125.4B | 38.94 | $8.41 | +1.05% |
| MDT | $83.32 | -0.56% | 107B | 23.28 | $3.58 | +3.41% |
| BSX | $62.07 | -5.51% | 92.2B | 25.97 | $2.39 | N/A |
| EW | $84.15 | +5.56% | 48.6B | 46.52 | $1.81 | N/A |
| BRKRP | $292.10 | +1.58% | 44.2B | N/A | N/A | +0.54% |
| PHG | $27.47 | -0.58% | 26.3B | 25.20 | $1.09 | +3.53% |
| DXCM | $61.57 | -1.80% | 23.8B | 29.46 | $2.09 | N/A |
Stock Comparison
NPCE vs BSX-PA Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NPCE is priced at $16.80, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NPCE's ROE is -1.06%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BSX-PA's competition here
NPCE vs ABT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ABT has a market cap of 158.4B. Regarding current trading prices, NPCE is priced at $16.80, while ABT trades at $91.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ABT's P/E ratio is 25.53. In terms of profitability, NPCE's ROE is -1.06%, compared to ABT's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ABT's competition here
NPCE vs SYK Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SYK has a market cap of 125.4B. Regarding current trading prices, NPCE is priced at $16.80, while SYK trades at $327.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SYK's P/E ratio is 38.94. In terms of profitability, NPCE's ROE is -1.06%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SYK's competition here
NPCE vs MDT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, MDT has a market cap of 107B. Regarding current trading prices, NPCE is priced at $16.80, while MDT trades at $83.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas MDT's P/E ratio is 23.28. In terms of profitability, NPCE's ROE is -1.06%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check MDT's competition here
NPCE vs BSX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BSX has a market cap of 92.2B. Regarding current trading prices, NPCE is priced at $16.80, while BSX trades at $62.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BSX's P/E ratio is 25.97. In terms of profitability, NPCE's ROE is -1.06%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NPCE is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BSX's competition here
NPCE vs EW Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, EW has a market cap of 48.6B. Regarding current trading prices, NPCE is priced at $16.80, while EW trades at $84.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas EW's P/E ratio is 46.52. In terms of profitability, NPCE's ROE is -1.06%, compared to EW's ROE of +0.10%. Regarding short-term risk, NPCE is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check EW's competition here
NPCE vs BRKRP Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BRKRP has a market cap of 44.2B. Regarding current trading prices, NPCE is priced at $16.80, while BRKRP trades at $292.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BRKRP's P/E ratio is N/A. In terms of profitability, NPCE's ROE is -1.06%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, NPCE is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BRKRP's competition here
NPCE vs PHG Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, NPCE is priced at $16.80, while PHG trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PHG's P/E ratio is 25.20. In terms of profitability, NPCE's ROE is -1.06%, compared to PHG's ROE of +0.08%. Regarding short-term risk, NPCE is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check PHG's competition here
NPCE vs DXCM Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, DXCM has a market cap of 23.8B. Regarding current trading prices, NPCE is priced at $16.80, while DXCM trades at $61.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas DXCM's P/E ratio is 29.46. In terms of profitability, NPCE's ROE is -1.06%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, NPCE is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check DXCM's competition here
NPCE vs STE Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, STE has a market cap of 21.8B. Regarding current trading prices, NPCE is priced at $16.80, while STE trades at $221.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas STE's P/E ratio is 30.89. In terms of profitability, NPCE's ROE is -1.06%, compared to STE's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check STE's competition here
NPCE vs ZBH Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ZBH has a market cap of 17.9B. Regarding current trading prices, NPCE is priced at $16.80, while ZBH trades at $91.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ZBH's P/E ratio is 26.45. In terms of profitability, NPCE's ROE is -1.06%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NPCE is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check ZBH's competition here
NPCE vs ABMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NPCE is priced at $16.80, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NPCE's ROE is -1.06%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ABMD's competition here
NPCE vs ALGN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, NPCE is priced at $16.80, while ALGN trades at $189.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ALGN's P/E ratio is 33.62. In terms of profitability, NPCE's ROE is -1.06%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, NPCE is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ALGN's competition here
NPCE vs SNN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, NPCE is priced at $16.80, while SNN trades at $31.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SNN's P/E ratio is 22.07. In terms of profitability, NPCE's ROE is -1.06%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SNN's competition here
NPCE vs PODD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PODD has a market cap of 13.3B. Regarding current trading prices, NPCE is priced at $16.80, while PODD trades at $189.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PODD's P/E ratio is 54.47. In terms of profitability, NPCE's ROE is -1.06%, compared to PODD's ROE of +0.17%. Regarding short-term risk, NPCE is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check PODD's competition here
NPCE vs PEN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, NPCE is priced at $16.80, while PEN trades at $329.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PEN's P/E ratio is 72.78. In terms of profitability, NPCE's ROE is -1.06%, compared to PEN's ROE of +0.13%. Regarding short-term risk, NPCE is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check PEN's competition here
NPCE vs GMED Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, GMED has a market cap of 12.8B. Regarding current trading prices, NPCE is priced at $16.80, while GMED trades at $94.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas GMED's P/E ratio is 24.20. In terms of profitability, NPCE's ROE is -1.06%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NPCE is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check GMED's competition here
NPCE vs SWAV Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NPCE is priced at $16.80, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NPCE's ROE is -1.06%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NPCE is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SWAV's competition here
NPCE vs BIO-B Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BIO-B has a market cap of 8.1B. Regarding current trading prices, NPCE is priced at $16.80, while BIO-B trades at $299.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BIO-B's P/E ratio is 10.75. In terms of profitability, NPCE's ROE is -1.06%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BIO-B's competition here
NPCE vs BIO Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, NPCE is priced at $16.80, while BIO trades at $287.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BIO's P/E ratio is 10.33. In terms of profitability, NPCE's ROE is -1.06%, compared to BIO's ROE of +0.11%. Regarding short-term risk, NPCE is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BIO's competition here
NPCE vs GKOS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, NPCE is priced at $16.80, while GKOS trades at $121.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas GKOS's P/E ratio is -37.05. In terms of profitability, NPCE's ROE is -1.06%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, NPCE is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check GKOS's competition here
NPCE vs BRKR Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, NPCE is priced at $16.80, while BRKR trades at $36.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BRKR's P/E ratio is -243.63. In terms of profitability, NPCE's ROE is -1.06%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, NPCE is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check BRKR's competition here
NPCE vs NARI Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NPCE is priced at $16.80, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas NARI's P/E ratio is -59.24. In terms of profitability, NPCE's ROE is -1.06%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NPCE is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check NARI's competition here
NPCE vs IRTC Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, NPCE is priced at $16.80, while IRTC trades at $122.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas IRTC's P/E ratio is -88.02. In terms of profitability, NPCE's ROE is -1.06%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, NPCE is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check IRTC's competition here
NPCE vs TMDX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, TMDX has a market cap of 3.8B. Regarding current trading prices, NPCE is priced at $16.80, while TMDX trades at $110.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas TMDX's P/E ratio is 22.81. In terms of profitability, NPCE's ROE is -1.06%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, NPCE is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TMDX's competition here
NPCE vs AXNX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NPCE is priced at $16.80, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NPCE's ROE is -1.06%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NPCE is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AXNX's competition here
NPCE vs LIVN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, NPCE is priced at $16.80, while LIVN trades at $64.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas LIVN's P/E ratio is -14.43. In terms of profitability, NPCE's ROE is -1.06%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, NPCE is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check LIVN's competition here
NPCE vs ITGR Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, NPCE is priced at $16.80, while ITGR trades at $86.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ITGR's P/E ratio is 29.76. In terms of profitability, NPCE's ROE is -1.06%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, NPCE is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ITGR's competition here
NPCE vs NUVA Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NPCE is priced at $16.80, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NPCE's ROE is -1.06%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NPCE is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check NUVA's competition here
NPCE vs AXGN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, AXGN has a market cap of 2B. Regarding current trading prices, NPCE is priced at $16.80, while AXGN trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas AXGN's P/E ratio is -115.44. In terms of profitability, NPCE's ROE is -1.06%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, NPCE is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check AXGN's competition here
NPCE vs ESTA Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, NPCE is priced at $16.80, while ESTA trades at $66.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ESTA's P/E ratio is -38.53. In terms of profitability, NPCE's ROE is -1.06%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, NPCE is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check ESTA's competition here
NPCE vs AORT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, NPCE is priced at $16.80, while AORT trades at $37.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas AORT's P/E ratio is 188.90. In terms of profitability, NPCE's ROE is -1.06%, compared to AORT's ROE of +0.02%. Regarding short-term risk, NPCE is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check AORT's competition here
NPCE vs AHCO Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, AHCO has a market cap of 1.7B. Regarding current trading prices, NPCE is priced at $16.80, while AHCO trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas AHCO's P/E ratio is -24.62. In terms of profitability, NPCE's ROE is -1.06%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NPCE is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AHCO's competition here
NPCE vs ATEC Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, NPCE is priced at $16.80, while ATEC trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ATEC's P/E ratio is -11.35. In terms of profitability, NPCE's ROE is -1.06%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, NPCE is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check ATEC's competition here
NPCE vs INSP Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, NPCE is priced at $16.80, while INSP trades at $56.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas INSP's P/E ratio is 11.51. In terms of profitability, NPCE's ROE is -1.06%, compared to INSP's ROE of +0.21%. Regarding short-term risk, NPCE is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check INSP's competition here
NPCE vs UFPT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, NPCE is priced at $16.80, while UFPT trades at $200.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas UFPT's P/E ratio is 22.84. In terms of profitability, NPCE's ROE is -1.06%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NPCE is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check UFPT's competition here
NPCE vs TNDM Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, NPCE is priced at $16.80, while TNDM trades at $20.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas TNDM's P/E ratio is -6.70. In terms of profitability, NPCE's ROE is -1.06%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, NPCE is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TNDM's competition here
NPCE vs PRCT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, NPCE is priced at $16.80, while PRCT trades at $24.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PRCT's P/E ratio is -14.16. In terms of profitability, NPCE's ROE is -1.06%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, NPCE is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PRCT's competition here
NPCE vs BFLY Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, NPCE is priced at $16.80, while BFLY trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BFLY's P/E ratio is -17.21. In terms of profitability, NPCE's ROE is -1.06%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, NPCE is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BFLY's competition here
NPCE vs PMI Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PMI has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $16.80, while PMI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PMI's P/E ratio is -1.13. In terms of profitability, NPCE's ROE is -1.06%, compared to PMI's ROE of +2.17%. Regarding short-term risk, NPCE is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PMI's competition here
NPCE vs HSKA Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NPCE is priced at $16.80, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NPCE's ROE is -1.06%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NPCE is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check HSKA's competition here
NPCE vs CNMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CNMD has a market cap of 1.2B. Regarding current trading prices, NPCE is priced at $16.80, while CNMD trades at $38.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CNMD's P/E ratio is 25.38. In terms of profitability, NPCE's ROE is -1.06%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, NPCE is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CNMD's competition here
NPCE vs AVNS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NPCE is priced at $16.80, while AVNS trades at $24.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas AVNS's P/E ratio is -15.73. In terms of profitability, NPCE's ROE is -1.06%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NPCE is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check AVNS's competition here
NPCE vs IRMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.80, while IRMD trades at $88.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas IRMD's P/E ratio is 52.79. In terms of profitability, NPCE's ROE is -1.06%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NPCE is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check IRMD's competition here
NPCE vs SILK Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.80, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SILK's P/E ratio is -18.96. In terms of profitability, NPCE's ROE is -1.06%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NPCE is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SILK's competition here
NPCE vs FNA Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NPCE is priced at $16.80, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas FNA's P/E ratio is -19.83. In terms of profitability, NPCE's ROE is -1.06%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NPCE is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check FNA's competition here
NPCE vs LMRI Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, LMRI has a market cap of 922.7M. Regarding current trading prices, NPCE is priced at $16.80, while LMRI trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas LMRI's P/E ratio is -14.55. In terms of profitability, NPCE's ROE is -1.06%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, NPCE is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check LMRI's competition here
NPCE vs INMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, INMD has a market cap of 912.4M. Regarding current trading prices, NPCE is priced at $16.80, while INMD trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas INMD's P/E ratio is 10.07. In terms of profitability, NPCE's ROE is -1.06%, compared to INMD's ROE of +0.15%. Regarding short-term risk, NPCE is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check INMD's competition here
NPCE vs SSII Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SSII has a market cap of 872.6M. Regarding current trading prices, NPCE is priced at $16.80, while SSII trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SSII's P/E ratio is -72.67. In terms of profitability, NPCE's ROE is -1.06%, compared to SSII's ROE of -0.30%. Regarding short-term risk, NPCE is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SSII's competition here
NPCE vs CSII Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NPCE is priced at $16.80, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CSII's P/E ratio is -20.83. In terms of profitability, NPCE's ROE is -1.06%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NPCE is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CSII's competition here
NPCE vs IART Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, IART has a market cap of 823.8M. Regarding current trading prices, NPCE is priced at $16.80, while IART trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas IART's P/E ratio is -1.57. In terms of profitability, NPCE's ROE is -1.06%, compared to IART's ROE of -0.44%. Regarding short-term risk, NPCE is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check IART's competition here
NPCE vs CBLL Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CBLL has a market cap of 797.2M. Regarding current trading prices, NPCE is priced at $16.80, while CBLL trades at $21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CBLL's P/E ratio is -14.51. In terms of profitability, NPCE's ROE is -1.06%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, NPCE is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check CBLL's competition here
NPCE vs CRY Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NPCE is priced at $16.80, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CRY's P/E ratio is 425.71. In terms of profitability, NPCE's ROE is -1.06%, compared to CRY's ROE of +0.02%. Regarding short-term risk, NPCE is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CRY's competition here
NPCE vs BVS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BVS has a market cap of 679.7M. Regarding current trading prices, NPCE is priced at $16.80, while BVS trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BVS's P/E ratio is 30.58. In terms of profitability, NPCE's ROE is -1.06%, compared to BVS's ROE of +0.14%. Regarding short-term risk, NPCE is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BVS's competition here
NPCE vs BWAY Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BWAY has a market cap of 642.1M. Regarding current trading prices, NPCE is priced at $16.80, while BWAY trades at $16.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BWAY's P/E ratio is 90.94. In terms of profitability, NPCE's ROE is -1.06%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, NPCE is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BWAY's competition here
NPCE vs SRDX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NPCE is priced at $16.80, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NPCE's ROE is -1.06%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, NPCE is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SRDX's competition here
NPCE vs SIBN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SIBN has a market cap of 597.1M. Regarding current trading prices, NPCE is priced at $16.80, while SIBN trades at $13.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SIBN's P/E ratio is -30.73. In terms of profitability, NPCE's ROE is -1.06%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, NPCE is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SIBN's competition here
NPCE vs APEN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NPCE is priced at $16.80, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas APEN's P/E ratio is -9.43. In terms of profitability, NPCE's ROE is -1.06%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NPCE is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check APEN's competition here
NPCE vs TCMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, TCMD has a market cap of 570.4M. Regarding current trading prices, NPCE is priced at $16.80, while TCMD trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas TCMD's P/E ratio is 30.57. In terms of profitability, NPCE's ROE is -1.06%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, NPCE is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TCMD's competition here
NPCE vs CTKB Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CTKB has a market cap of 565.6M. Regarding current trading prices, NPCE is priced at $16.80, while CTKB trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CTKB's P/E ratio is -8.46. In terms of profitability, NPCE's ROE is -1.06%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, NPCE is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CTKB's competition here
NPCE vs ZIMV Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NPCE is priced at $16.80, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NPCE's ROE is -1.06%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NPCE is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check ZIMV's competition here
NPCE vs VREX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, VREX has a market cap of 525.3M. Regarding current trading prices, NPCE is priced at $16.80, while VREX trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas VREX's P/E ratio is -7.64. In terms of profitability, NPCE's ROE is -1.06%, compared to VREX's ROE of -0.14%. Regarding short-term risk, NPCE is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check VREX's competition here
NPCE vs OFIX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, OFIX has a market cap of 495.8M. Regarding current trading prices, NPCE is priced at $16.80, while OFIX trades at $12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas OFIX's P/E ratio is -5.30. In terms of profitability, NPCE's ROE is -1.06%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, NPCE is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check OFIX's competition here
NPCE vs PACB Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PACB has a market cap of 471.1M. Regarding current trading prices, NPCE is priced at $16.80, while PACB trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PACB's P/E ratio is -0.86. In terms of profitability, NPCE's ROE is -1.06%, compared to PACB's ROE of -11.23%. Regarding short-term risk, NPCE is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PACB's competition here
NPCE vs KIDS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, KIDS has a market cap of 409.3M. Regarding current trading prices, NPCE is priced at $16.80, while KIDS trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas KIDS's P/E ratio is -9.58. In terms of profitability, NPCE's ROE is -1.06%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NPCE is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check KIDS's competition here
NPCE vs CERS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CERS has a market cap of 380.5M. Regarding current trading prices, NPCE is priced at $16.80, while CERS trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CERS's P/E ratio is -24.75. In terms of profitability, NPCE's ROE is -1.06%, compared to CERS's ROE of -0.26%. Regarding short-term risk, NPCE is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CERS's competition here
NPCE vs DCTH Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, DCTH has a market cap of 376.6M. Regarding current trading prices, NPCE is priced at $16.80, while DCTH trades at $10.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas DCTH's P/E ratio is 154.86. In terms of profitability, NPCE's ROE is -1.06%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, NPCE is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check DCTH's competition here
NPCE vs VMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, VMD has a market cap of 372.9M. Regarding current trading prices, NPCE is priced at $16.80, while VMD trades at $9.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas VMD's P/E ratio is 26.11. In terms of profitability, NPCE's ROE is -1.06%, compared to VMD's ROE of +0.11%. Regarding short-term risk, NPCE is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check VMD's competition here
NPCE vs LAB Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, LAB has a market cap of 350.9M. Regarding current trading prices, NPCE is priced at $16.80, while LAB trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas LAB's P/E ratio is -6.00. In terms of profitability, NPCE's ROE is -1.06%, compared to LAB's ROE of -0.18%. Regarding short-term risk, NPCE is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check LAB's competition here
NPCE vs CLPT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CLPT has a market cap of 349.4M. Regarding current trading prices, NPCE is priced at $16.80, while CLPT trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CLPT's P/E ratio is -13.09. In terms of profitability, NPCE's ROE is -1.06%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, NPCE is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CLPT's competition here
NPCE vs CATX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CATX has a market cap of 333.3M. Regarding current trading prices, NPCE is priced at $16.80, while CATX trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CATX's P/E ratio is -3.21. In terms of profitability, NPCE's ROE is -1.06%, compared to CATX's ROE of -0.41%. Regarding short-term risk, NPCE is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CATX's competition here
NPCE vs SMLR Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NPCE is priced at $16.80, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NPCE's ROE is -1.06%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, NPCE is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check SMLR's competition here
NPCE vs RXST Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, RXST has a market cap of 299.2M. Regarding current trading prices, NPCE is priced at $16.80, while RXST trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas RXST's P/E ratio is -7.63. In terms of profitability, NPCE's ROE is -1.06%, compared to RXST's ROE of -0.14%. Regarding short-term risk, NPCE is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check RXST's competition here
NPCE vs SENS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SENS has a market cap of 294.7M. Regarding current trading prices, NPCE is priced at $16.80, while SENS trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SENS's P/E ratio is -4.25. In terms of profitability, NPCE's ROE is -1.06%, compared to SENS's ROE of -1.04%. Regarding short-term risk, NPCE is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SENS's competition here
NPCE vs MASS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, MASS has a market cap of 251.9M. Regarding current trading prices, NPCE is priced at $16.80, while MASS trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas MASS's P/E ratio is -7.33. In terms of profitability, NPCE's ROE is -1.06%, compared to MASS's ROE of +0.13%. Regarding short-term risk, NPCE is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check MASS's competition here
NPCE vs MGRM Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NPCE is priced at $16.80, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas MGRM's P/E ratio is -11.11. In terms of profitability, NPCE's ROE is -1.06%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, NPCE is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check MGRM's competition here
NPCE vs SGHT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SGHT has a market cap of 235.5M. Regarding current trading prices, NPCE is priced at $16.80, while SGHT trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SGHT's P/E ratio is -5.89. In terms of profitability, NPCE's ROE is -1.06%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, NPCE is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SGHT's competition here
NPCE vs NVRO Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NPCE is priced at $16.80, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NPCE's ROE is -1.06%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NPCE is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check NVRO's competition here
NPCE vs ANIK Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ANIK has a market cap of 221.7M. Regarding current trading prices, NPCE is priced at $16.80, while ANIK trades at $15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ANIK's P/E ratio is -21.96. In terms of profitability, NPCE's ROE is -1.06%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, NPCE is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check ANIK's competition here
NPCE vs ELMD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, ELMD has a market cap of 220.1M. Regarding current trading prices, NPCE is priced at $16.80, while ELMD trades at $26.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas ELMD's P/E ratio is 25.62. In terms of profitability, NPCE's ROE is -1.06%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, NPCE is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check ELMD's competition here
NPCE vs PROF Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, PROF has a market cap of 211.5M. Regarding current trading prices, NPCE is priced at $16.80, while PROF trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas PROF's P/E ratio is -4.96. In terms of profitability, NPCE's ROE is -1.06%, compared to PROF's ROE of -0.80%. Regarding short-term risk, NPCE is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check PROF's competition here
NPCE vs EYES Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NPCE is priced at $16.80, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas EYES's P/E ratio is N/A. In terms of profitability, NPCE's ROE is -1.06%, compared to EYES's ROE of -3.17%. Regarding short-term risk, NPCE is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check EYES's competition here
NPCE vs AVR Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, AVR has a market cap of 205.3M. Regarding current trading prices, NPCE is priced at $16.80, while AVR trades at $5.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas AVR's P/E ratio is -2.19. In terms of profitability, NPCE's ROE is -1.06%, compared to AVR's ROE of -5.28%. Regarding short-term risk, NPCE is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check AVR's competition here
NPCE vs CVRX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, CVRX has a market cap of 203.1M. Regarding current trading prices, NPCE is priced at $16.80, while CVRX trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas CVRX's P/E ratio is -3.78. In terms of profitability, NPCE's ROE is -1.06%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, NPCE is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check CVRX's competition here
NPCE vs INGN Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, INGN has a market cap of 192M. Regarding current trading prices, NPCE is priced at $16.80, while INGN trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas INGN's P/E ratio is -8.20. In terms of profitability, NPCE's ROE is -1.06%, compared to INGN's ROE of -0.12%. Regarding short-term risk, NPCE is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check INGN's competition here
NPCE vs BSGM Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NPCE is priced at $16.80, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NPCE's ROE is -1.06%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, NPCE is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check BSGM's competition here
NPCE vs MDGS Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NPCE is priced at $16.80, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NPCE's ROE is -1.06%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NPCE is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check MDGS's competition here
NPCE vs QTI Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, QTI has a market cap of 178.3M. Regarding current trading prices, NPCE is priced at $16.80, while QTI trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas QTI's P/E ratio is -3.27. In terms of profitability, NPCE's ROE is -1.06%, compared to QTI's ROE of +3.64%. Regarding short-term risk, NPCE is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check QTI's competition here
NPCE vs TLSI Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, TLSI has a market cap of 175.9M. Regarding current trading prices, NPCE is priced at $16.80, while TLSI trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas TLSI's P/E ratio is -2.52. In terms of profitability, NPCE's ROE is -1.06%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, NPCE is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TLSI's competition here
NPCE vs QIPT Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NPCE is priced at $16.80, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NPCE's ROE is -1.06%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NPCE is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check QIPT's competition here
NPCE vs SNWV Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, SNWV has a market cap of 160.7M. Regarding current trading prices, NPCE is priced at $16.80, while SNWV trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas SNWV's P/E ratio is 45.61. In terms of profitability, NPCE's ROE is -1.06%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, NPCE is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check SNWV's competition here
NPCE vs APYX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, APYX has a market cap of 155.6M. Regarding current trading prices, NPCE is priced at $16.80, while APYX trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas APYX's P/E ratio is -13.78. In terms of profitability, NPCE's ROE is -1.06%, compared to APYX's ROE of -1.18%. Regarding short-term risk, NPCE is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check APYX's competition here
NPCE vs QTRX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, QTRX has a market cap of 154M. Regarding current trading prices, NPCE is priced at $16.80, while QTRX trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas QTRX's P/E ratio is -1.31. In terms of profitability, NPCE's ROE is -1.06%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, NPCE is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check QTRX's competition here
NPCE vs TMCI Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, TMCI has a market cap of 128.3M. Regarding current trading prices, NPCE is priced at $16.80, while TMCI trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas TMCI's P/E ratio is -2.13. In terms of profitability, NPCE's ROE is -1.06%, compared to TMCI's ROE of -0.62%. Regarding short-term risk, NPCE is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check TMCI's competition here
NPCE vs EDAP Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, EDAP has a market cap of 121.1M. Regarding current trading prices, NPCE is priced at $16.80, while EDAP trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas EDAP's P/E ratio is -4.14. In terms of profitability, NPCE's ROE is -1.06%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, NPCE is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check EDAP's competition here
NPCE vs NNOX Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, NNOX has a market cap of 120.7M. Regarding current trading prices, NPCE is priced at $16.80, while NNOX trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas NNOX's P/E ratio is -1.50. In terms of profitability, NPCE's ROE is -1.06%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, NPCE is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check NNOX's competition here
NPCE vs FONR Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, FONR has a market cap of 116.2M. Regarding current trading prices, NPCE is priced at $16.80, while FONR trades at $18.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas FONR's P/E ratio is 16.37. In terms of profitability, NPCE's ROE is -1.06%, compared to FONR's ROE of +0.04%. Regarding short-term risk, NPCE is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for NPCE.Check FONR's competition here
NPCE vs LUCD Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, LUCD has a market cap of 111M. Regarding current trading prices, NPCE is priced at $16.80, while LUCD trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas LUCD's P/E ratio is -1.57. In terms of profitability, NPCE's ROE is -1.06%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, NPCE is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check LUCD's competition here
NPCE vs RCEL Comparison April 2026
NPCE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NPCE stands at 565.6M. In comparison, RCEL has a market cap of 110.8M. Regarding current trading prices, NPCE is priced at $16.80, while RCEL trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NPCE currently has a P/E ratio of -25.45, whereas RCEL's P/E ratio is -2.69. In terms of profitability, NPCE's ROE is -1.06%, compared to RCEL's ROE of +4.77%. Regarding short-term risk, NPCE is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NPCE.Check RCEL's competition here